Key Developments: Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

47.27EUR
23 Jul 2014
Price Change (% chg)

€-0.33 (-0.70%)
Prev Close
€47.60
Open
€47.10
Day's High
€47.48
Day's Low
€47.10
Volume
825
Avg. Vol
1,490
52-wk High
€47.60
52-wk Low
€35.05

Search Stocks

Latest Key Developments (Source: Significant Developments)

Eli Lilly and Co and Immunocore Limited agreement to co-discover and co-develop novel cancer therapies
Wednesday, 16 Jul 2014 07:00am EDT 

Eli Lilly and Co and Immunocore Limited:Enters into co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies.Immunocore will receive an upfront fee of $15 mln per program for discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages.Says if Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive opt-in fee of $10 mln and will have option to continue co-development with Lilly on a cost-sharing and profit-sharing basis.Says if Immunocore does not exercise its option, it will be entitled to potential future milestone and royalty payments.  Full Article

Sanofi files patent infringement lawsuit against Eli Lilly-Reuters
Monday, 7 Jul 2014 08:00pm EDT 

Sanofi SA:Files lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it - Reuters.Seeks to halt Lilly's proposed commercial marketing in United States of treatment known as Abasria.Lawsuit follows narrower lawsuit filed in January, after Lilly and German partner Boehringer Ingelheim Corp applied with U.S. FDA to sell generic version of Sanofi's Lantus, whose active ingredient is insulin glargine.  Full Article

Yabao Pharmaceutical Group Co ltd enters partnership with Eli Lilly and Company to develop diabetes treatment
Monday, 7 Jul 2014 09:20am EDT 

Yabao Pharmaceutical Group Co Ltd:Enters into strategic partnership with Eli Lilly and Company to co-develop Lilly's glucokinase activator (GKA), LY2608204.Lilly's GKA has completed Phase 1 studies in US in addition to extensive pre-clinical development.Under the terms of the agreement, Yabao receives rights to develop and commercialize the GKA compound in China while Lilly retains rights in all other markets.Parties will collaborate to determine a strategic development plan for China, and Yabao will initially be responsible to perform and fund all development, with Lilly having future buy-in options for China.Financial terms were not disclosed.  Full Article

RaQualia Pharma Inc announces termination of joint development contract with Eli Lilly and Company
Thursday, 26 Jun 2014 08:30pm EDT 

RaQualia Pharma Inc:Announces termination of joint development contract that signed in Dec. 2010, with Eli Lilly and Company.Says contract concerning specific ion channels with the aim of analgesics creation.  Full Article

Eli Lilly and Co announces detailed results from two phase III studies testing both doses of Dulaglutide vs. Insulin Glargine
Monday, 16 Jun 2014 06:15pm EDT 

Eli Lilly and Co:Releases detailed results from two trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with lower risk for hypoglycemia.1,2Dulaglutide is investigational glucagon-like peptide-1 (GLP-1) receptor agonist being studied for the treatment of type 2 diabetes.  Full Article

Eli Lilly and Co declares third-quarter 2014 dividend
Monday, 16 Jun 2014 02:15pm EDT 

Eli Lilly and Co:Declares dividend for third quarter of 2014 of $0.49 per share on outstanding common stock.Dividend is payable Sept. 10, 2014 to shareholders of record at the close of business on Aug. 15, 2014.  Full Article

Eli Lilly and Co's investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials
Monday, 16 Jun 2014 11:45am EDT 

Eli Lilly and Co:Two phase III clinical trials studying efficacy and safety of investigational compound empagliflozin in type 2 diabetes (T2D) were presented, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced.In two-year study, empagliflozin demonstrated significantly greater decreases in hemoglobin A1C body weight and blood pressure compared with glimepiride as add-on to metformin in adults with T2D.In 52-week study of obese adults with T2D on high insulin doses with or without metformin, adding empagliflozin to multiple daily insulin injections significantly reduced blood glucose and body weight with lower insulin doses compared with placebo.  Full Article

Eli Lilly and Co's basal insulin peglispro shows novel mechanism of action
Saturday, 14 Jun 2014 01:00pm EDT 

Eli Lilly and Co:Announces new data regarding mechanism of action of basal insulin peglispro (BIL).When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the liver, BIL showed less activity in peripheral tissues, such as muscle and fat, than insulin glargine.1.In this study, researchers measured both glucose disposal rate (GDR) and endogenous glucose production (EGP) rate to characterize peripheral vs. hepatic insulin action.1.BIL, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials, and is among several diabetes molecules in Lilly's late-stage pipeline.  Full Article

Eli Lilly and Co's once-weekly dulaglutide shows similar reductions in average blood glucose levels as once-daily liraglutide in head-to-head trial
Saturday, 14 Jun 2014 01:00pm EDT 

Eli Lilly and Co:Releases detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg.Non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.1.Head-to-head study compared safety and efficacy of dulaglutide and liraglutide, two glucagon-like peptide-1 (GLP-1) receptor agonists.At primary endpoint of 26 weeks, once-weekly dulaglutide 1.5 mg and once-daily liraglutide 1.8 mg significantly reduced HbA1c levels from baseline (-1.42 percent and -1.36 percent, respectively), with dulaglutide demonstrating non-inferiority compared to liraglutide.Similar majority of patients in both treatment groups (68 pct.) reached the American Diabetes Association's recommended HbA1c target of less than 7 percent.1 Patients treated with once-weekly dulaglutide.And once-daily liraglutide showed significant weight reductions from baseline (-2.9 kg, -3.6 kg, respectively).This weight reduction was statistically greater in liraglutide treatment arm.1.  Full Article

Eli Lilly and Co results of phase III hepatocellular carcinoma trial did not meet its primary endpoint
Wednesday, 11 Jun 2014 08:00am EDT 

Eli Lilly and Co:Says that the Phase III REACH trial of CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint.Says overall survival favored the CYRAMZA arm but was not statistically significant.Encouraging single agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression.  Full Article

Photo

Spooked by probes, pharma executives ask: should I leave China?

SHANGHAI - China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months. Others are thinking of going for good.

No consensus analysis data available.
Search Stocks